Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more
Grace Therapeutics, Inc. (GRCE) - Net Assets
Latest net assets as of September 2025: $62.82 Million USD
Based on the latest financial reports, Grace Therapeutics, Inc. (GRCE) has net assets worth $62.82 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($66.58 Million) and total liabilities ($3.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $62.82 Million |
| % of Total Assets | 94.36% |
| Annual Growth Rate | 20.59% |
| 5-Year Change | 19.67% |
| 10-Year Change | 150.81% |
| Growth Volatility | 107.35 |
Grace Therapeutics, Inc. - Net Assets Trend (2010–2025)
This chart illustrates how Grace Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Grace Therapeutics, Inc. (2010–2025)
The table below shows the annual net assets of Grace Therapeutics, Inc. from 2010 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $66.61 Million | +7.88% |
| 2024-03-31 | $61.74 Million | -9.14% |
| 2023-03-31 | $67.95 Million | -37.24% |
| 2022-03-31 | $108.27 Million | +94.52% |
| 2021-03-31 | $55.66 Million | +328.35% |
| 2020-03-31 | $12.99 Million | +17.65% |
| 2019-03-31 | $11.04 Million | +73.44% |
| 2018-03-31 | $6.37 Million | -68.30% |
| 2016-03-31 | $20.09 Million | -24.37% |
| 2015-03-31 | $26.56 Million | -11.21% |
| 2014-03-31 | $29.91 Million | +214.90% |
| 2013-03-31 | $9.50 Million | -34.74% |
| 2012-03-31 | $14.55 Million | +149.49% |
| 2011-03-31 | $5.83 Million | +45.19% |
| 2010-03-31 | $4.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Grace Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21711341500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $-6.04 Million | -9.06% |
| Other Components | $293.33 Million | 440.38% |
| Total Equity | $66.61 Million | 100.00% |
Grace Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Grace Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Seafco Public Company Limited
BK:SEAFCO
|
$39.72 Million |
|
Victoria Investama Tbk
JK:VICO
|
$39.73 Million |
|
Nasmed Ozel Saglik Hizmetleri Ticaret AS
IS:EGEPO
|
$39.73 Million |
|
GreenMobility A/S
CO:GREENM
|
$39.74 Million |
|
Taiwan Takisawa Technology Co Ltd
TWO:6609
|
$39.70 Million |
|
Zimmite Taiwan Ltd
TWO:8435
|
$39.69 Million |
|
Principal Capital Public Company Limited
BK:PRINC
|
$39.68 Million |
|
Whiting Petroleum Corporation
PINK:WLLBW
|
$39.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Grace Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 61,743,000 to 66,610,000, a change of 4,867,000 (7.9%).
- Net loss of 9,568,000 reduced equity.
- New share issuances of 14,999,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.57 Million | -14.36% |
| Share Issuances | $15.00 Million | +22.52% |
| Other Changes | $-564.00K | -0.85% |
| Total Change | $- | 7.88% |
Book Value vs Market Value Analysis
This analysis compares Grace Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.81x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.05x to 0.81x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-03-31 | $89.25 | $4.45 | x |
| 2011-03-31 | $54.58 | $4.45 | x |
| 2012-03-31 | $103.90 | $4.45 | x |
| 2013-03-31 | $62.66 | $4.45 | x |
| 2014-03-31 | $170.17 | $4.45 | x |
| 2015-03-31 | $120.06 | $4.45 | x |
| 2016-03-31 | $90.45 | $4.45 | x |
| 2018-03-31 | $17.48 | $4.45 | x |
| 2019-03-31 | $9.77 | $4.45 | x |
| 2020-03-31 | $7.37 | $4.45 | x |
| 2021-03-31 | $22.53 | $4.45 | x |
| 2022-03-31 | $17.63 | $4.45 | x |
| 2023-03-31 | $9.14 | $4.45 | x |
| 2024-03-31 | $8.30 | $4.45 | x |
| 2025-03-31 | $5.51 | $4.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Grace Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-14.36%) is above the historical average (-81.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -37.54% | 0.00% | 0.00x | 2.22x | $-1.91 Million |
| 2011 | -52.73% | -10592.29% | 0.00x | 1.90x | $-3.66 Million |
| 2012 | -44.93% | -62421.58% | 0.00x | 1.09x | $-7.99 Million |
| 2013 | -70.88% | -951.66% | 0.06x | 1.25x | $-7.68 Million |
| 2014 | -34.89% | -2318.29% | 0.01x | 1.37x | $-13.43 Million |
| 2015 | -4.98% | -611.68% | 0.01x | 1.12x | $-3.98 Million |
| 2016 | -23.21% | -16777.63% | 0.00x | 1.05x | $-6.67 Million |
| 2018 | -261.49% | 0.00% | 0.00x | 2.79x | $-17.29 Million |
| 2019 | -356.41% | 0.00% | 0.00x | 3.34x | $-40.47 Million |
| 2020 | -196.34% | 0.00% | 0.00x | 1.76x | $-26.81 Million |
| 2021 | -35.35% | -10039.80% | 0.00x | 1.12x | $-25.24 Million |
| 2022 | -9.07% | 0.00% | 0.00x | 1.19x | $-20.65 Million |
| 2023 | -62.44% | 0.00% | 0.00x | 1.16x | $-49.22 Million |
| 2024 | -20.82% | 0.00% | 0.00x | 1.19x | $-19.03 Million |
| 2025 | -14.36% | 0.00% | 0.00x | 1.08x | $-16.23 Million |
Industry Comparison
This section compares Grace Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $62.82 Million | -37.54% | 0.06x | $39.72 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |